[Ip-health] NIH responds (sort of) to questions about Petragen, Inc., a start-up company incorporated in the state of Delaware

James Love james.love at keionline.org
Fri Oct 9 12:33:04 PDT 2020


This is how the NIH responds when asked questions about a proposed
exclusive license to a company that has no web page or SEC filings.

---------- Forwarded message ---------
From: Williams, Benfeard (NIH/NHLBI) [E] <benfeard.williams at nih.gov>
Date: Fri, Oct 9, 2020 at 3:12 PM
Subject: RE: Petragen, Inc., a start-up company incorporated in the state
of Delaware
To: James Love <james.love at keionline.org>
Cc: Claire Cassedy <claire.cassedy at keionline.org>, Kathryn Ardizzone <
kathryn.ardizzone at keionline.org>, Luis Gil Abinader <
luis.gil.abinader at keionline.org>


Dear Jamie Love,



Please find responses to your questions below.



   1. Can you tell us who are the principals in this company, which does
   not appear to have any web page or SEC filings?
      1. To the extent any of this information may be provided in the
      company’s application, it is protected as business confidential.
   2. Is there any foreign ownership in the company?
      1. To the extent any of this information may be provided in the
      company’s application, it is protected as business confidential.
   3. Is the NIH negotiating in parallel a waiver of US manufacturing?
      1. We cannot confirm or deny whether we are negotiating such
      agreements.
   4. What is the stage of development of this technology?  Have there been
   any clinical trials?
      1. This is an early stage technology. There have been no clinical
      trials.
   5. Will the NIH include any international reference pricing obligations
   on the company, given the President's campaign promises on this issue?
      1. The agreement and its royalty terms are yet to be negotiated and
      are confidential to the company.



Best regards,

Benfeard Williams



*---*

*Benfeard L. Williams, II, Ph.D.* | Office of Technology Transfer and
Development

National Heart, Lung, and Blood Institute | National Institutes of Health

31 Center Drive, Room 4A29, MSC2479, Bethesda, MD 20892-2479

Email: benfeard.williams at nih.gov





*From:* James Love <james.love at keionline.org>
*Sent:* Thursday, September 24, 2020 9:03 AM
*To:* Williams, Benfeard (NIH/NHLBI) [E] <benfeard.williams at nih.gov>
*Cc:* Claire Cassedy <claire.cassedy at keionline.org>; Kathryn Ardizzone <
kathryn.ardizzone at keionline.org>; Luis Gil Abinader <
luis.gil.abinader at keionline.org>
*Subject:* Petragen, Inc., a start-up company incorporated in the state of
Delaware




Dear Benfeard Williams, II, Ph.D,



1. Can you tell us who are the principals in this company, which does not
appear to have any web page or SEC filings?



2.  Is there any foreign ownership in the company?



3. Is the NIH negotiating in parallel a waiver of US manufacturing?



4.  What is the stage of development of this technology?  Have there been
any clinical trials?



5.  Will the NIH include any international reference pricing obligations on
the company, given the President's campaign promises on this issue?



Jamie



-- 

James Love.  Knowledge Ecology International

U.S. Mobile +1.202.361.3040

U.S. office phone +1.202.332.2670
http://www.keionline.org <http://www.keionline.org/donate.html>

twitter.com/jamie_love


-- 
James Love.  Knowledge Ecology International
U.S. Mobile +1.202.361.3040
U.S. office phone +1.202.332.2670
http://www.keionline.org <http://www.keionline.org/donate.html>
twitter.com/jamie_love


More information about the Ip-health mailing list